BILIARY TRACT CANCER
Clinical trials for BILIARY TRACT CANCER explained in plain language.
Never miss a new study
Get alerted when new BILIARY TRACT CANCER trials appear
Sign up with your email to follow new studies for BILIARY TRACT CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New triple therapy targets Hard-to-Treat bile duct cancer
Disease control Not yet recruitingThis study tests a combination of three drugs (disitamab vedotin, lenvatinib, and a PD-1 inhibitor) in 65 adults with advanced HER2-positive bile duct cancer that cannot be removed by surgery. The goal is to see if the combo shrinks tumors and controls the disease. Participants w…
Matched conditions: BILIARY TRACT CANCER
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated May 26, 2026 04:22 UTC
-
New combo aims to shrink bile duct tumors before surgery
Disease control Not yet recruitingThis study tests whether adding the drug envafolimab to standard chemotherapy (gemcitabine and cisplatin) before surgery can reduce cancer cells in patients with bile duct cancer at high risk of coming back. About 34 adults aged 18-80 with this cancer will receive the drug combin…
Matched conditions: BILIARY TRACT CANCER
Phase: PHASE2 • Sponsor: Sir Run Run Shaw Hospital • Aim: Disease control
Last updated May 26, 2026 04:20 UTC
-
New drug cocktail aims to stop bile duct cancer recurrence
Disease control Not yet recruitingThis study tests whether combining two drugs—adebrelimab (given by IV) and S-1 (taken as pills)—can help prevent bile duct cancer from returning after surgery. About 40 adults who had their cancer completely removed will receive the treatment for about 4 months. Researchers will …
Matched conditions: BILIARY TRACT CANCER
Phase: PHASE2 • Sponsor: Xingjun Guo • Aim: Disease control
Last updated May 26, 2026 04:18 UTC
-
New hope for bile duct cancer patients who've run out of options
Disease control Not yet recruitingThis study tests a new drug called BL-B01D1 against standard treatments for people with advanced bile duct cancer that has worsened after chemotherapy and immunotherapy. About 538 adults will be randomly assigned to receive either the new drug or a doctor-chosen treatment. The ma…
Matched conditions: BILIARY TRACT CANCER
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 04:11 UTC